Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, Greenlee H, Hansen E, Kamal AH, Kamdar MM, LeGrand S, Mackey S, McDowell MR, Moryl N, Nabell LM, Nesbit S; BCPS, O'Connor N, Rabow MW, Rickerson E, Shatsky R, Sindt J, Urba SG, Youngwerth JM, Hammond LJ, Gurski LA.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):977-1007. doi: 10.6004/jnccn.2019.0038.

PMID:
31390582
2.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

3.

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.

Lin VTG, Nabell LM, Spencer SA, Carroll WR, Harada S, Yang ES.

J Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.

4.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK.

Breast Cancer Res Treat. 2018 Oct;171(3):637-648. doi: 10.1007/s10549-018-4852-5. Epub 2018 Jun 25.

5.

Implementation and utilization of the molecular tumor board to guide precision medicine.

Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.

Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22. Review.

6.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
7.

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.

Bowles DW, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A.

Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2. doi: 10.1016/j.clcc.2016.03.004. Epub 2016 Mar 31.

PMID:
27118441
8.

Induction chemotherapy for head and neck cancer: is there still a role?

Ove R, Nabell LM.

Future Oncol. 2016 Jul;12(13):1595-608. doi: 10.2217/fon-2016-0073. Epub 2016 Apr 20. Review.

PMID:
27093876
9.

Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach CE, Morlandt AB, Agarwal G, Hartman YE, Carroll WR, Richman JS, Clemons LK, Nabell LM, Zinn KR.

Clin Cancer Res. 2015 Aug 15;21(16):3658-66. doi: 10.1158/1078-0432.CCR-14-3284. Epub 2015 Apr 22.

10.

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ.

Ann Oncol. 2015 Jul;26(7):1481-7. doi: 10.1093/annonc/mdv196. Epub 2015 Apr 21.

11.

A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.

Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS.

Breast Cancer Res Treat. 2014 Nov;148(1):99-106. doi: 10.1007/s10549-014-3131-3. Epub 2014 Sep 26.

PMID:
25257727
12.

Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.

Rosenthal EL, Chung TK, Carroll WR, Clemons L, Desmond R, Nabell L.

Ann Surg Oncol. 2014 Dec;21(13):4263-9. doi: 10.1245/s10434-014-3878-0. Epub 2014 Jul 8.

PMID:
25001094
13.

Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.

Paluri R, Nabell L, Borak S, Peker D.

Hematol Oncol. 2015 Dec;33(4):206-11. doi: 10.1002/hon.2147. Epub 2014 May 21. Review.

PMID:
24850172
14.

African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis.

Isayeva T, Xu J, Dai Q, Whitley AC, Bonner J, Nabell L, Spencer S, Carroll W, Jones G, Ragin C, Brandwein-Gensler M.

Hum Pathol. 2014 Feb;45(2):310-9. doi: 10.1016/j.humpath.2013.09.006. Epub 2013 Dec 16.

PMID:
24355195
15.

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.

16.

Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.

Wagner MM, Curé JK, Caudell JJ, Spencer SA, Nabell LM, Carroll WR, Bonner JA.

Radiat Oncol. 2012 Dec 21;7:219. doi: 10.1186/1748-717X-7-219.

17.

Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.

Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, Spencer S, Magnuson JS, Rosenthal EL.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1275-81. doi: 10.1016/j.ijrobp.2012.09.030. Epub 2012 Nov 22.

18.

Chemotherapy-resistant metastatic breast cancer.

Marquette C, Nabell L.

Curr Treat Options Oncol. 2012 Jun;13(2):263-75. doi: 10.1007/s11864-012-0184-6.

PMID:
22528367
19.

Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer.

Dragovic AF, Caudell JJ, Spencer SA, Carroll WR, Nabell LA, Bonner JA.

Head Neck. 2013 Mar;35(3):381-7. doi: 10.1002/hed.22977. Epub 2012 Mar 9.

PMID:
22407986
20.

By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.

Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE.

J Natl Compr Canc Netw. 2012 Jan;10(1):7-13.

PMID:
22223865
21.

Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.

Dragovic AF, Bonner JA, Spencer SA, Nabell LM, Carroll WR, Caudell JJ.

Head Neck. 2011 Nov;33(11):1551-6. doi: 10.1002/hed.21634. Epub 2010 Dec 9.

PMID:
21990218
22.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

23.

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD.

Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9.

24.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
25.

NCCN Task Force Report: breast cancer in the older woman.

Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP.

J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-25; quiz S26-7. Review.

PMID:
18597715
26.

Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5. doi: 10.1016/j.ijrobp.2008.04.048. Epub 2008 Jul 16.

PMID:
18635320
27.

Cancer of the tonsil presenting as central nervous system metastasis: A case report.

Dobelbower MC, Nabell L, Markert J, Carroll W, Said-Al-Naief N, Meredith R.

Head Neck. 2009 Jan;31(1):127-30. doi: 10.1002/hed.20834.

PMID:
18442058
28.

Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81. doi: 10.1016/j.ijrobp.2007.10.040. Epub 2008 Mar 20.

PMID:
18355979
29.

Invasive breast cancer.

Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2007 Mar;5(3):246-312. Review. No abstract available.

PMID:
17439758
30.

Genetic/familial high-risk assessment: breast and ovarian.

Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Feb;4(2):156-76. No abstract available.

PMID:
16451772
31.

Breast cancer.

Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 May;3(3):238-89. No abstract available.

PMID:
16002000
32.

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E.

J Clin Oncol. 2004 Jul 15;22(14):2856-64.

PMID:
15254053
33.

Improving the effectiveness of adjuvant psychological treatment for women with breast cancer: the feasibility of providing online support.

Owen JE, Klapow JC, Roth DL, Nabell L, Tucker DC.

Psychooncology. 2004 Apr;13(4):281-92.

PMID:
15054732
34.

Docetaxel with concurrent radiotherapy in head and neck cancer.

Nabell L, Spencer S.

Semin Oncol. 2003 Dec;30(6 Suppl 18):89-93. Review.

PMID:
14727247
35.

Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.

Gruszecki AC, Wehrli G, Ragland BD, Reddy VV, Nabell L, Garcia-Hernandez A, Marques MB.

Am J Hematol. 2002 Mar;69(3):228-31.

36.

NCCN Practice Guidelines for Breast Cancer.

Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A; National Comprehensive Cancer Network.

Oncology (Williston Park). 2000 Nov;14(11A):33-49.

PMID:
11195418
37.
38.

Signal transduction by a CD16/CD7/Jak2 fusion protein.

Sakai I, Nabell L, Kraft AS.

J Biol Chem. 1995 Aug 4;270(31):18420-7.

39.
40.

17 beta-estradiol acts directly on the clonal osteoblastic cell line UMR106.

Gray TK, Flynn TC, Gray KM, Nabell LM.

Proc Natl Acad Sci U S A. 1987 Sep;84(17):6267-71.

41.

Actin filament organization of the Dunning R3327 rat prostatic adenocarcinoma system: correlation with metastatic potential.

Zachary JM, Cleveland G, Kwock L, Lawrence T, Weissman RM, Nabell L, Fried FA, Staab EV, Risinger MA, Lin S.

Cancer Res. 1986 Feb;46(2):926-32.

Supplemental Content

Loading ...
Support Center